GNRH1 and prostate cancer: The analysis did, however, reveal two FDA-approved drugs that potentially target MTCs in both TI and TC regions: bivalirudin, a reversible direct thrombin inhibitor (44), and degarelix, a GnRH antagonist used in the treatment of prostate cancer (45).